14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DEUS vs BMED: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DEUS Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)
DEUS Overall Winner
6-Pillar Tally: DEUS 0 – 0 BMED (6 Tie)
Matrix Metrics: DEUS 2 – 1 BMED
As of Nov 16, 2026, Xtrackers Russell US Multifactor ETF (DEUS) is the stronger overall head-to-head candidate over iShares Health Innovation Active ETF (BMED) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). DEUS carries a Unified Composite Score of 47.3/100 (HOLD) at $67.94 (N/M Forward P/E, N/A operating margin), whereas BMED carries 51.8/100 (HOLD) at $35.93 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While BMED currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. DEUS 47.3/100 HOLD), DEUS captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DEUS vs BMED. Trailing 12-month operating profitability (DEUS N/A vs BMED N/A) and valuation multiples (DEUS N/M vs BMED N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DEUS vs BMED Key Questions & Quantitative Answers
As of Nov 16, 2026, Xtrackers Russell US Multifactor ETF (DEUS) is the stronger overall head-to-head candidate over iShares Health Innovation Active ETF (BMED) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). DEUS carries a Unified Composite Score of 47.3/100 (HOLD) at $67.94 (N/M Forward P/E, N/A operating margin), whereas BMED carries 51.8/100 (HOLD) at $35.93 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While BMED currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. DEUS 47.3/100 HOLD), DEUS captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
DEUS and BMED split Growth & Scale metrics: DEUS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BMED at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, DEUS generates N/A in USD-normalized revenue versus N/A for BMED. In operating R&D and SG&A reinvestment, DEUS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMED.
DEUS and BMED trade at balanced relative valuation multiples. DEUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BMED trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DEUS (N/A ROE) versus BMED (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, DEUS carries 14.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 16% Vol realized risk). By comparison, BMED carries 42.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.61β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.